Carmustine Injection

This product and its metabolites can cross-link with nucleic acids through alkylation, and may also produce anti-cancer effects by changing proteins. It can interact with DNA polymerase in the body and has effects on all stages of proliferative cells. It is teratogenic to rabbits and mice.

Main ingredient: Carmustine. Molecular formula: C5H9Cl2N3O2 Molecular weight: 214.05

This product is a light yellow clear liquid.

Because it can pass through the blood-brain barrier, it is effective against brain tumors (malignant glioma, brain stem glioma, medulloblastoma, astrocytoma, ependymoma), brain metastases and meningeal leukemia, malignant lymphoma, multiple myeloma, and in combination with other drugs, malignant melanoma.

Intravenous injection: 100 mg/m2 per body surface area, once a day for 2-3 days; or 200 mg/m2, once, repeated every 6-8 weeks. Dissolve in 150 ml of 5% glucose or saline and drip rapidly.

After a single intravenous injection, bone marrow suppression often occurs 4 to 6 weeks after medication, the lowest white blood cell value is seen in 5 to 6 weeks, and gradually recovers in 6 to 7 weeks. However, multiple medications can delay recovery to 10 to 12 weeks. After a single intravenous injection, the lowest platelet value is seen in 4 to 5 weeks, and it recovers within 6 to 7 weeks. The decrease in platelets is often more serious than that of white blood cells. Thrombophlebitis may occur at the intravenous injection site. Large doses may produce encephalomyelopathy. Long-term treatment may produce pulmonary interstitial or pulmonary fibrosis. Sometimes even pulmonary complications occur after 1 to 2 courses of treatment, and some patients cannot recover. In addition, gastrointestinal reactions such as nausea and vomiting may occur, which may occur 2 hours after medication and often last for 4 to 6 hours. It has an impact on both the liver and kidneys. Liver damage can often be recovered. Kidney toxicity can be seen in azotemia, decreased function, and kidney shrinkage. There are reports of secondary leukemia with this product. There is also the possibility of teratogenicity. This product can inhibit testicular or egg function, causing amenorrhea or sperm deficiency.

Patients with a history of allergic reaction to this drug and pregnant and lactating women are contraindicated to use this drug.

When this product is used in combination chemotherapy regimens, anticancer drugs that have a serious effect of reducing leukocytes and platelets, or produce severe gastrointestinal reactions should be avoided.

Keep in a dark place, tightly sealed and stored in a frozen place below 5℃.

2ml:0.125g